Alcohol Use Disorder Treatment Denied by Insurance: How to Appeal

Alcohol use disorder (AUD) is a chronic, serious medical condition — yet insurance coverage for its treatment is routinely denied in ways that would be unthinkable for comparable chronic physical diseases. If you have been denied coverage for naltrexone, Vivitrol, medically supervised detox, or residential rehabilitation, this guide will help you understand your rights and build a strong appeal.

Why Insurance Companies Deny AUD Treatment

Vivitrol (injectable naltrexone) and oral naltrexone: FDA-approved for alcohol use disorder, these medications reduce cravings and relapse rates. Insurers frequently require Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization and demand failure of oral naltrexone before approving the injectable formulation — even when a patient's history documents adherence challenges that make the injectable clinically preferable. Some plans refuse coverage for any AUD medication because they classify it as a "behavioral" rather than medical condition.

Acamprosate (Campral): Another FDA-approved AUD medication that faces prior authorization barriers and is sometimes excluded from formularies entirely, forcing patients to rely on older, less-tolerated alternatives.

Medically Supervised Alcohol Detoxification: Alcohol withdrawal is one of the few substance withdrawal syndromes that can be immediately life-threatening (risk of seizures, delirium tremens). Despite this, insurers impose arbitrary day limits on detox coverage, require outpatient detox for patients who need inpatient monitoring, or apply criteria more restrictive than clinical guidelines. A denial of medically necessary inpatient alcohol detox for a patient with a history of withdrawal seizures is both clinically dangerous and legally vulnerable.

Residential Rehabilitation: Insurers frequently deny residential rehab by citing lack of outpatient treatment failure documentation, arbitrary day limits, or claims that ongoing care is "not medically necessary" because the patient is "medically stable." This ignores the psychiatric and social complexity that makes residential care necessary.

Mental Health Parity Act (MHPAEA) Explained" class="auto-link">mhpaea-and-the-aca">Federal Law: MHPAEA and the ACA

The Mental Health Parity and Addiction Equity Act explicitly covers substance use disorders including AUD. Under MHPAEA, your insurer cannot:

• Apply stricter prior authorization requirements to AUD treatment than to comparable chronic medical conditions
• Impose day limits on detox or rehab that would not apply to comparable medical rehabilitation
• Use more restrictive medical necessity criteria for SUD residential care than for medical/surgical residential care

The ACA requires all individual and small group plans to cover mental health and substance use disorder treatment as an Essential Health Benefit, with no lifetime or annual dollar limits.

A 2023 federal rule strengthened MHPAEA enforcement by requiring plans to conduct and document comparative analyses of how they apply nonquantitative treatment limitations (NQTLs) — criteria like prior authorization and step therapy — to mental health/SUD versus medical/surgical benefits. You can request your plan's NQTL analysis.

State-Level Protections

Many states have enacted AUD-specific coverage mandates that go beyond federal law:

• Several states prohibit prior authorization requirements for AUD medications approved by the FDA
• Some states mandate coverage of medically supervised detox without day limits when clinically necessary
• State Medicaid programs in most states cover FDA-approved AUD pharmacotherapy under enhanced federal Medicaid match rates

Contact your state insurance commissioner's office or a patient advocacy organization to identify state-specific protections.

Building Your Appeal

For medication denials (naltrexone/Vivitrol):

• Include your prescriber's documentation of why the prescribed formulation is medically necessary
• Document any prior medication trials, adherence challenges, or clinical factors supporting the requested treatment
• Cite FDA labeling and APA/ASAM treatment guidelines that support the medication
• Invoke MHPAEA if comparable injectable medications for chronic physical conditions are covered without similar restrictions

For detox denials:

• Include documentation of withdrawal risk factors: prior withdrawal seizures, prior delirium tremens, current daily consumption, comorbid medical conditions
• Cite ASAM's Clinical Practice Guidelines for Withdrawal Management
• For concurrent review denials (e.g., cutting inpatient days), request an urgent peer-to-peer review between your physician and the insurer's medical director
• Invoke MHPAEA and compare to the insurer's criteria for inpatient management of other medically unstable conditions

For residential rehab denials:

• Complete an ASAM Criteria Level of Care assessment and submit with the appeal
• Document prior outpatient treatment attempts and outcomes
• Include treating clinician documentation of psychiatric complexity, social instability, or high relapse risk that make residential care medically necessary

The Timeline That Matters

For standard (non-urgent) denials, you typically have 180 days to file an internal appeal. For concurrent review denials (during active treatment), the timeline may be as short as 72 hours. Act immediately when a concurrent denial arrives — contact the treatment facility's utilization review team right away.

Fight Back With ClaimBack

Alcohol use disorder is a disease, not a choice — and effective treatment should not be denied by bureaucratic criteria that violate federal law. ClaimBack helps you build the appeal your situation deserves.

Start your alcohol use disorder insurance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter That Gets Results
• What Is Medical Necessity — and How to Prove It to Your Insurer
• Internal vs. External Insurance Appeals: Which Path Is Right for You?